Pat Dorsey
Dorsey Asset Management
Pat Dorsey Royalty PharmaPlc stake
total: 39
Dorsey Asset Management RPRX trades
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2025 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Pat Dorsey holds 2,456,528 Royalty PharmaPlc (RPRX) shares with a market value of roughly $137.74M accounting for 8.82% of the overall portfolio. To date, the estimated cost basis is nearly $36.83 for "buy" trades and estimated average "sell" price is $38.64. Dorsey Asset Management first purchased RPRX in 2025 Q3, initially acquiring about 2.35M shares. Since the initial investment in Royalty PharmaPlc (RPRX), Dorsey Asset Management has made 3 more transactions.
When did Pat Dorsey buy Royalty PharmaPlc (RPRX)?
Pat Dorsey first invested in Royalty PharmaPlc (RPRX) in 2025 Q3 at the reported quarter-end price of $35.28 per share.
What's the cost basis of Dorsey Asset Management's RPRX stake?
The estimated cost basis for Royalty PharmaPlc (RPRX) stake is around $36.83 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $36.83
- Weighted AVG sell price:
- $38.64
Pat Dorsey's historical trades in Royalty PharmaPlc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
8.82%
|
2,456,528
|
$56.07
|
$137,737,525
|
+7.90% (+179,958)
|
+0.65%
|
|
2026 Q1
|
8.70%
|
2,276,570
|
$47.97
|
$109,207,063
|
+0.76% (+17,101)
|
+0.07%
|
|
2025 Q4
|
7.59%
|
2,259,469
|
$38.64
|
$87,305,882
|
-3.87% (-90,980)
|
-0.32%
|
|
2025 Q3
|
7.45%
|
2,350,449
|
$35.28
|
$82,923,841
|
new
|
+7.45%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.